News and Announcements
Actinogen Medical Announces Landmark Research on Excess Cortisol and Alzheimer’s Disease
- Published July 28, 2016 12:39PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
28th July 2016, ASX Announcement
- Australian CSIRO and university funded AIBL study links excess cortisol and Alzheimer’s disease.
- Anti-Alzheimer’s compound Xanamem™ in clinical testing blocks high cortisol (“stress” hormone) associated with disease progression.
- Landmark research on disease mechanism and Actinogen Medical’s Xanamem™ presented at Alzheimer’s Association International Conference (AAIC) in Toronto 22nd-28th July.
Actinogen Medical (ASX:ACW) announced today results of its lead compound, Xanamem™, a novel, orally administered 11β-HSD1 inhibitor, which demonstrated in a Phase I study that it significantly inhibited production of cortisol in healthy volunteers and successfully crossed the blood-brain barrier. A separate study, the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL), sponsored by the CSIRO and a number of Australian universities, showed a correlation between elevated cortisol in the blood of a healthy aged population and the subsequent development of Alzheimer’s disease in these individuals. When individuals also evidenced a broad build-up of beta-amyloid plaques in the brain, their chances of developing Alzheimer’s disease increased even further. The AIBL study (n=416) concluded that targeting ways to lower excess cortisol should be undertaken in battling Alzheimer’s disease in the elderly. Both studies were presented at the AAIC, the world’s largest Alzheimer’s Dementia meeting, taking place this week in Toronto, Canada.
To view the full announcement, please click on the button below.
To download the more information on Cortisol Hypothesis AAIC Supplement, please click on the link below.